KR101732751B1 - Ｒｅｌ-ｎ-［6-［(2ｒ,6ｓ)-2,6-디메틸-4-모르폴리닐］-3-피리디닐］-2-메틸-4'-(트리플루오로메톡시)-［1,1'-비페닐］-3-카르복스아미드를 포함한 국소 제약 조성물 - Google Patents

Ｒｅｌ-ｎ-［6-［(2ｒ,6ｓ)-2,6-디메틸-4-모르폴리닐］-3-피리디닐］-2-메틸-4'-(트리플루오로메톡시)-［1,1'-비페닐］-3-카르복스아미드를 포함한 국소 제약 조성물 Download PDF

Info

Publication number
KR101732751B1
KR101732751B1 KR1020127004353A KR20127004353A KR101732751B1 KR 101732751 B1 KR101732751 B1 KR 101732751B1 KR 1020127004353 A KR1020127004353 A KR 1020127004353A KR 20127004353 A KR20127004353 A KR 20127004353A KR 101732751 B1 KR101732751 B1 KR 101732751B1
Authority
KR
South Korea
Prior art keywords
present
composition
skin
trifluoromethoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127004353A
Other languages
English (en)
Korean (ko)
Other versions
KR20120097482A (ko
Inventor
안드레아스 프릿쯔
카리느 꼬르셀르
멜린다 에니코 그루베사
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20120097482A publication Critical patent/KR20120097482A/ko
Application granted granted Critical
Publication of KR101732751B1 publication Critical patent/KR101732751B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127004353A 2009-07-21 2010-07-20 Ｒｅｌ-ｎ-［6-［(2ｒ,6ｓ)-2,6-디메틸-4-모르폴리닐］-3-피리디닐］-2-메틸-4'-(트리플루오로메톡시)-［1,1'-비페닐］-3-카르복스아미드를 포함한 국소 제약 조성물 Active KR101732751B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22714109P 2009-07-21 2009-07-21
US61/227,141 2009-07-21
US29588410P 2010-01-18 2010-01-18
US61/295,884 2010-01-18
PCT/EP2010/060470 WO2011009852A2 (en) 2009-07-21 2010-07-20 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR20120097482A KR20120097482A (ko) 2012-09-04
KR101732751B1 true KR101732751B1 (ko) 2017-05-04

Family

ID=42633096

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127004353A Active KR101732751B1 (ko) 2009-07-21 2010-07-20 Ｒｅｌ-ｎ-［6-［(2ｒ,6ｓ)-2,6-디메틸-4-모르폴리닐］-3-피리디닐］-2-메틸-4'-(트리플루오로메톡시)-［1,1'-비페닐］-3-카르복스아미드를 포함한 국소 제약 조성물

Country Status (16)

Country Link
US (1) US8722672B2 (enExample)
EP (1) EP2456422B1 (enExample)
JP (2) JP6106434B2 (enExample)
KR (1) KR101732751B1 (enExample)
CN (2) CN103893184B (enExample)
AR (1) AR077490A1 (enExample)
AU (1) AU2010275240A1 (enExample)
BR (1) BR112012001340B1 (enExample)
CA (1) CA2768457C (enExample)
ES (1) ES2576740T3 (enExample)
HK (1) HK1199217A1 (enExample)
IN (1) IN2012DN00239A (enExample)
MX (1) MX2012000954A (enExample)
RU (1) RU2589699C2 (enExample)
TW (1) TW201107314A (enExample)
WO (1) WO2011009852A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2012166241A1 (en) * 2011-06-02 2012-12-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
MX353017B (es) 2011-09-28 2017-12-18 Titan Wood Ltd Paneles de fibras de densidad media.
AU2014220339B2 (en) * 2013-02-25 2016-12-01 Sun Pharmaceutical Industries Limited Oral formulation and suspension of an oncology drug
US10266523B2 (en) 2015-03-30 2019-04-23 Crystal Pharmatech Co., Ltd. Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN105330658B (zh) * 2015-12-09 2017-09-19 苏州明锐医药科技有限公司 索尼吉布的制备方法
CN112773805B (zh) * 2019-11-11 2024-05-10 中国科学院脑科学与智能技术卓越创新中心 缺血性脑损伤的新型治疗药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
IT1265001B1 (it) * 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
FR2719475B1 (fr) * 1994-05-05 1996-06-07 Oreal Composition cosmétique et/ou dermatologique à gélifiant polymérique cationique, ses utilisations notamment pour la dépigmentation de la peau.
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
RU2207124C1 (ru) * 2002-04-24 2003-06-27 Закрытое акционерное общество "Брынцалов-А" Крем "брамизил" противогрибкового действия
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
DE102006014454B3 (de) 2006-03-29 2007-11-08 Hoffmann, Frank Stanzvorrichtung mit Zuführeinrichtung
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
CN101445508B (zh) * 2008-11-21 2011-08-31 南京威尔化工有限公司 异山梨醇二甲醚的合成方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators

Also Published As

Publication number Publication date
WO2011009852A2 (en) 2011-01-27
CA2768457C (en) 2018-01-23
HK1199217A1 (en) 2015-06-26
KR20120097482A (ko) 2012-09-04
US8722672B2 (en) 2014-05-13
JP2012533598A (ja) 2012-12-27
EP2456422B1 (en) 2016-03-16
US20120122866A1 (en) 2012-05-17
TW201107314A (en) 2011-03-01
CN103893184A (zh) 2014-07-02
CA2768457A1 (en) 2011-01-27
BR112012001340B1 (pt) 2021-08-03
CN103893184B (zh) 2016-03-02
AU2010275240A1 (en) 2012-02-02
CN102481249A (zh) 2012-05-30
IN2012DN00239A (enExample) 2015-05-01
RU2012105752A (ru) 2013-08-27
JP6106434B2 (ja) 2017-03-29
ES2576740T3 (es) 2016-07-11
WO2011009852A3 (en) 2012-01-19
AR077490A1 (es) 2011-08-31
MX2012000954A (es) 2012-02-28
JP2015199753A (ja) 2015-11-12
RU2589699C2 (ru) 2016-07-10
BR112012001340A2 (pt) 2016-03-15
EP2456422A2 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
KR101732751B1 (ko) Ｒｅｌ-ｎ-［6-［(2ｒ,6ｓ)-2,6-디메틸-4-모르폴리닐］-3-피리디닐］-2-메틸-4'-(트리플루오로메톡시)-［1,1'-비페닐］-3-카르복스아미드를 포함한 국소 제약 조성물
CN114667147B (zh) 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
US9114110B2 (en) Suspension type topical formulations comprising cyclic depdipeptide
CA3159633A1 (en) Mrgprx2 antagonists and uses thereof
TW201113258A (en) Pharmaceutical compositions and solid forms
US20200247816A1 (en) Topical phosphoinositide 3-kinase inhibitors
EP3750883B1 (en) Aminoalkyl compound
EP2158908B1 (en) Composition for transdermal administration
AU2007238816B2 (en) Methods for modulating formation and progression of cellulite
JP6408489B2 (ja) 治療配合物（ｃｏｍｐｏｕｎｄｓ）
JPS59184125A (ja) 抗糸状菌剤
CN110621654B (zh) Trpv1调节剂化合物
KR20220161356A (ko) 자발적 수용이 개선된 조성물
JP2009507858A (ja) キノリン誘導体および抗腫瘍薬としての使用
NZ615551B2 (en) Suspension type topical formulations comprising cyclic depsipeptide
JP2003267966A (ja) フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150717

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160706

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170426

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170426

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210421

Start annual number: 5

End annual number: 5